Combination Vaccination Before HIV Treatment Interruption

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

July 31, 2010

Study Completion Date

November 30, 2010

Conditions
HIV Infections
Interventions
BIOLOGICAL

Remune and ALVAC

"* Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);~* Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or~* Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."

Trial Locations (3)

K1H 8L6

The Ottawa Hospital, General Campus, Ottawa

H2W 1T8

CHUM Hotel-Dieu, Montreal

H2X 2P4

Montreal Chest Institute, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Ontario HIV Treatment Network

NETWORK

collaborator

CIHR Canadian HIV Trials Network

NETWORK

lead

Ottawa Hospital Research Institute

OTHER